ViroPharma acquired the U.S. rights to Vancocin from Eli Lilly in December 2004.    From Wordnik.com.  [ViroPharma Shares 'Absolute Floor' Seen At $9 to $10] Reference

Sendek is skeptical the FDA would grant such a waiver for a generic version of Vancocin.    From Wordnik.com.  [ViroPharma's Generic Worries Create Attractive Entry Point] Reference

Management blamed the shortfall to an unexpected reduction in wholesaler inventory levels for Vancocin.    From Wordnik.com.  [Legal Wins Boost Drug Stocks] Reference

ViroPharma shares were hit hard on worries of generic competition for its anti-infective agent Vancocin.    From Wordnik.com.  [Pharma Stocks Flex Some Muscle] Reference

ViroPharma sells Vancocin, an oral antibiotic used to treat bacterial infections of the lower digestive tract.    From Wordnik.com.  [The Five Best Buy Calls] Reference

Lazard Capital Markets said it was skeptical the FDA would grant such a waiver for a generic version of Vancocin.    From Wordnik.com.  [Pharma Stocks Flex Some Muscle] Reference

Earlier this month, AstraZeneca said it acquired the rights to Vancocin for the India and Nepal markets for an undisclosed sum.    From Wordnik.com.  [ViroPharma Shares 'Absolute Floor' Seen At $9 to $10] Reference

"With uncertainty on both the generic situation and the underlying demand for Vancocin, we remain on the sidelines with ViroPharma.".    From Wordnik.com.  [Legal Wins Boost Drug Stocks] Reference

"We do not believe that the FDA will allow a developer of a generic Vancocin to substitute dissolution studies for a clinical trial.".    From Wordnik.com.  [ViroPharma's Generic Worries Create Attractive Entry Point] Reference

"We do not believe that the FDA will allow a developer of a generic Vancocin to substitute dissolution studies for a clinical trial," it said.    From Wordnik.com.  [Pharma Stocks Flex Some Muscle] Reference

Vancocin is used to treat hospital-acquired bacterial infections in the lower gastrointestinal tract caused by the bacterium Clostridium difficile.    From Wordnik.com.  [Bush's FDA - Perpetual Leaker of Insider Information] Reference

But if diarrhea continues and becomes severe, Vancocin is a treatment of last resort for very sick patients which means there is no room for error.    From Wordnik.com.  [Bush's FDA - Perpetual Leaker of Insider Information] Reference

Piper Jaffray maintained an "outperform" rating on ViroPharma and said generic threats to lead drug Vancocin would not likely hit the market until 2010.    From Wordnik.com.  [ViroPharma's Sales Estimates Still 'Highly Conservative'] Reference

ViroPharma, of Exton, Pa., whose Vancocin antibiotic would be in direct competition with Optimer's anti-infective if approved, slumped 1.25, or 9.9%, to 11.32.    From Wordnik.com.  [Drug Test Sinks Sangamo; OM Group, KKR Crater] Reference

"However, we recognize that based on the bioequivalence guidance provided to us by the FDA, a generic Vancocin could enter the market earlier than our previous estimate of 2010.".    From Wordnik.com.  [Pharma Stocks Flex Some Muscle] Reference

For more severe symptoms vancomycin (Vancocin) may be used.    From Wordnik.com.  [Health News from Medical News Today] Reference

Have you guys any inventory build in the channel for Vancocin?.    From Wordnik.com.  [Biotech Sector and Stocks Analysis from Seeking Alpha] Reference

First and foremost, our Vancocin guidance assumes no generic competition.    From Wordnik.com.  [Biotech Sector and Stocks Analysis from Seeking Alpha] Reference

Fidaxomicin has an edge over Vancocin to treat clostridium infection: Optimer.    From Wordnik.com.  [DWS Full News Feed] Reference

Regarding Vancocin net sales, we had increased our guidance and tightened our range.    From Wordnik.com.  [Biotech Sector and Stocks Analysis from Seeking Alpha] Reference

Investors apparently are discounting sales of Vancocin until the uncertainty is over.    From Wordnik.com.  [Fool.com: The Motley Fool] Reference

Vancocin is currently the only US FDA-approved therapy for Clostridium difficile Infection.    From Wordnik.com.  [DWS Full News Feed] Reference

In the comparative periods in 2008, the Company only had cost of sales related to Vancocin.    From Wordnik.com.  [Medindia Health News] Reference

Subjects with confirmed CDI received either fidaxomicin (200 mg q12h) or Vancocin (125 mg q6h).    From Wordnik.com.  [TradingMarkets] Reference

Clinical cure rates for fidaxomicin and Vancocin were similar in these two strain type subgroups.    From Wordnik.com.  [TradingMarkets] Reference

The incidence of adverse events and serious adverse events was similar in the fidaxomicin and Vancocin arms.    From Wordnik.com.  [TradingMarkets] Reference

In the trial, fidaxomicin met the primary endpoint of non-inferiority in clinical cure compared to Vancocin®.    From Wordnik.com.  [RedOrbit News - Technology] Reference

In the trial, fidaxomicin met the primary endpoint of non-inferiority in clinical cure compared to Vancocin (R).    From Wordnik.com.  [TradingMarkets] Reference

The company gets most of its revenue from Vancocin, an antibiotic that treats certain infections of the lower digestive tract.    From Wordnik.com.  [BusinessWeek.com -- Top News] Reference

And if generic Vancocin does come on the market, how commercially viable do you think development programs will be for C. diff?.    From Wordnik.com.  [Biotech Sector and Stocks Analysis from Seeking Alpha] Reference

Only 12. 8% of patients treated with fidaxomicin experienced a recurrence vs. 25. 3% of patients treated with Vancocin (p = 0.002).    From Wordnik.com.  [BioSpace.com Featured News and Stories] Reference

Vancocin and Cinryze cost of sales includes the cost of materials and distribution costs and excludes amortization of product rights.    From Wordnik.com.  [GuruFocus Updates -] Reference

The FDA is likely to follow an advisory committee recommendation to approve generic versions of Viropharma's (Nasdaq: VPHM) Vancocin.    From Wordnik.com.  [Fool.com: The Motley Fool] Reference